CD4<sup>+</sup> T cell help in cancer immunology and immunotherapy.

Borst J; Ahrends T; Bąbała N; Melief CJM; Kastenmüller W

doi:10.1038/s41577-018-0044-0

CD4⁺ T cell help in cancer immunology and immunotherapy.

Affiliations

1. Division of Tumour Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
Authors
Borst J¹
Ahrends T¹
Bąbała N¹
(3 authors)
2. Leiden University Medical Center and ISA Pharmaceuticals, Leiden, Netherlands.
Authors
Melief CJM²
(1 author)
3. Institute for Systems Immunology, Würzburg, Germany.
Authors
Kastenmüller W³
(1 author)

ORCIDs linked to this article

Nature reviews. Immunology, 01 Oct 2018, 18(10):635-647
https://doi.org/10.1038/s41577-018-0044-0 PMID: 30057419

Review

Abstract

Cancer immunotherapy aims to promote the activity of cytotoxic T lymphocytes (CTLs) within a tumour, assist the priming of tumour-specific CTLs in lymphoid organs and establish efficient and durable antitumour immunity. During priming, help signals are relayed from CD4⁺ T cells to CD8⁺ T cells by specific dendritic cells to optimize the magnitude and quality of the CTL response. In this Review, we highlight the cellular dynamics and membrane receptors that mediate CD4⁺ T cell help and the molecular mechanisms of the enhanced antitumour activity of CTLs. We outline how deficient CD4⁺ T cell help reduces the response of CTLs and how maximizing CD4⁺ T cell help can improve outcomes in cancer immunotherapy strategies.

Full text links

Read article at publisher's site: https://doi.org/10.1038/s41577-018-0044-0

References

Articles referenced by this article (140)

Oncology meets immunology: the cancer-immunity cycle.
Chen DS, Mellman I
Immunity, (1):1-10 2013
MED: 23890059
Systemic Immunity Is Required for Effective Cancer Immunotherapy.
Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, Gherardini PF, Prestwood TR, Chabon J, Bendall SC, Fong L, Nolan GP, Engleman EG
Cell, (3):487-502.e15 2017
MED: 28111070
Vaccines targeting helper T cells for cancer immunotherapy.
Melssen M, Slingluff CL Jr
Curr Opin Immunol, 85-92 2017
MED: 28755541
Multiple roles for CD4+ T cells in anti-tumor immune responses.
Kennedy R, Celis E
Immunol Rev, 129-144 2008
MED: 18363998
Helping the CD8(+) T-cell response.
Bevan MJ
Nat Rev Immunol, (8):595-602 2004
MED: 15286726
Cooperation between CD4+ and CD8+ T cells: when, where, and how.
Castellino F, Germain RN
Annu Rev Immunol, 519-540 2006
MED: 16551258
CD4(+) T-cell help amplifies innate signals for primary CD8(+) T-cell immunity.
Bedoui S, Heath WR, Mueller SN
Immunol Rev, (1):52-64 2016
MED: 27319342
Robust Anti-viral Immunity Requires Multiple Distinct T Cell-Dendritic Cell Interactions.
Eickhoff S, Brewitz A, Gerner MY, Klauschen F, Komander K, Hemmi H, Garbi N, Kaisho T, Germain RN, Kastenmuller W
Cell, (6):1322-1337 2015
MED: 26296422
Spatiotemporally Distinct Interactions with Dendritic Cell Subsets Facilitates CD4+ and CD8+ T Cell Activation to Localized Viral Infection.
Hor JL, Whitney PG, Zaid A, Brooks AG, Heath WR, Mueller SN
Immunity, (3):554-565 2015
MED: 26297566
Imaging of the cross-presenting dendritic cell subsets in the skin-draining lymph node.
Kitano M, Yamazaki C, Takumi A, Ikeno T, Hemmi H, Takahashi N, Shimizu K, Fraser SE, Hoshino K, Kaisho T, Okada T
Proc Natl Acad Sci U S A, (4):1044-1049 2016
MED: 26755602

Show 10 more references (10 of 140)

Citations & impact

Impact metrics

770

Citations

Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/45759180

Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/45759180

Smart citations by scite.ai
Explore citation contexts and check if this article has been supported or disputed.
https://scite.ai/reports/10.1038/s41577-018-0044-0

Supporting

Mentioning

Contrasting

943

Article citations

Engineering dendritic cell biomimetic membrane as a delivery system for tumor targeted therapy.
Liu H, Lu Y, Zong J, Zhang B, Li X, Qi H, Yu T, Li Y
J Nanobiotechnology, 22(1):663, 27 Oct 2024
Cited by: 0 articles | PMID: 39465376 | PMCID: PMC11520105
Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Patients with Extensive-Stage Small Cell Lung Cancer Harboring Less Than 4 Metastatic Sites May Benefit from Immune Checkpoint Inhibitor Rechallenge by Reshaping Tumor Microenvironment.
Shang X, Zhang C, Lv Y, Zhang X, Guo K, Li H, Wang H
Immunotargets Ther, 13:571-583, 26 Oct 2024
Cited by: 0 articles | PMID: 39478941 | PMCID: PMC11523948
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Differentiation fate of a stem-like CD4 T cell controls immunity to cancer.
Cardenas MA, Prokhnevska N, Sobierajska E, Gregorova P, Medina CB, Valanparambil RM, Greenwald R, DelBalzo L, Bilen MA, Joshi SS, Narayan VM, Master VA, Sanda MG, Kissick HT
Nature, 23 Oct 2024
Cited by: 0 articles | PMID: 39443797
Sustained lymphocyte decreases after treatment for early breast cancer.
Dixon-Douglas J, Virassamy B, Clarke K, Hun M, Luen SJ, Savas P, van Geelen CT, David S, Francis PA, Salgado R, Michiels S, Loi S
NPJ Breast Cancer, 10(1):94, 21 Oct 2024
Cited by: 0 articles | PMID: 39433772 | PMCID: PMC11493948
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Heterogeneity in peripheral blood immune lymphocyte subsets predicts the response of immunotherapy or chemoradiotherapy in advanced lung cancer: an analysis across different pathological types, treatment modalities and age.
Miao C, Chen Y, Zhang H, Zhao W, Wang C, Ma Z, Zhu S, Hu X
Front Immunol, 15:1464728, 17 Oct 2024
Cited by: 0 articles | PMID: 39483483 | PMCID: PMC11524866
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

Go to all (770) article citations

Search life-sciences literature (45,104,206 articles, preprints and more)

CD4⁺ T cell help in cancer immunology and immunotherapy.

Affiliations

Authors

Authors

Authors

ORCIDs linked to this article

Abstract

Full text links

References

Oncology meets immunology: the cancer-immunity cycle.

Systemic Immunity Is Required for Effective Cancer Immunotherapy.

Vaccines targeting helper T cells for cancer immunotherapy.

Multiple roles for CD4+ T cells in anti-tumor immune responses.

Helping the CD8(+) T-cell response.

Cooperation between CD4+ and CD8+ T cells: when, where, and how.

CD4(+) T-cell help amplifies innate signals for primary CD8(+) T-cell immunity.

Robust Anti-viral Immunity Requires Multiple Distinct T Cell-Dendritic Cell Interactions.

Spatiotemporally Distinct Interactions with Dendritic Cell Subsets Facilitates CD4+ and CD8+ T Cell Activation to Localized Viral Infection.

Imaging of the cross-presenting dendritic cell subsets in the skin-draining lymph node.

Citations & impact

Impact metrics

Citations of article over time

Alternative metrics

Smart citations by scite.ai
Explore citation contexts and check if this article has been supported or disputed.
https://scite.ai/reports/10.1038/s41577-018-0044-0

Article citations

Engineering dendritic cell biomimetic membrane as a delivery system for tumor targeted therapy.

Patients with Extensive-Stage Small Cell Lung Cancer Harboring Less Than 4 Metastatic Sites May Benefit from Immune Checkpoint Inhibitor Rechallenge by Reshaping Tumor Microenvironment.

Differentiation fate of a stem-like CD4 T cell controls immunity to cancer.

Sustained lymphocyte decreases after treatment for early breast cancer.

Heterogeneity in peripheral blood immune lymphocyte subsets predicts the response of immunotherapy or chemoradiotherapy in advanced lung cancer: an analysis across different pathological types, treatment modalities and age.

Similar Articles

CD8⁺ cytotoxic T lymphocytes in cancer immunotherapy: A review.

Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor.

Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy.

Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.

Partnerships & funding

Similar Articles

CD8⁺ cytotoxic T lymphocytes in cancer immunotherapy: A review.
J Cell Physiol, 234(6):8509-8521, 22 Nov 2018

Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor.
J Immunol, 164(7):3902-3912, 01 Apr 2000

Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy.

Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
Clin Cancer Res, 19(16):4508-4520, 28 May 2013

Search life-sciences literature (45,104,206 articles, preprints and more)

CD4+ T cell help in cancer immunology and immunotherapy.

Author information

Affiliations

Authors

Authors

Authors

ORCIDs linked to this article

Abstract

Full text links

References

Citations & impact

Impact metrics

Citations of article over time

Alternative metrics

Article citations

Similar Articles

Partnerships & funding

CD4⁺ T cell help in cancer immunology and immunotherapy.